---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-23-000041"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:54:45.945389+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q3 2023: revenue $581M (+15% YoY), VOXZOGO $123M (+155%), cuts ROCTAVIAN guidance

## Summary
- Q3 total revenue $581.3M (+15% YoY), GAAP net income $40.4M vs loss $6.7M, GAAP diluted EPS $0.21 vs ($0.04).
- VOXZOGO revenue $123.1M (+155% YoY); full-year guidance raised to $435-455M from $400-440M.
- ROCTAVIAN revenue $0.8M; full-year guidance slashed to <$10M from $50-150M due to pricing delays.
- Full-year 2023 total revenue guidance narrowed to $2.39-2.47B; Non-GAAP diluted EPS guided $1.90-2.05.
- Management expects 2024 revenue to approach $3B; VOXZOGO age expansions in US and EU; hypochondroplasia trial to start.

## SEC filing metadata
- accession: 0001048477-23-000041
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/bmrn-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-23-000041
- JSON: https://secwatch.observer/filing/0001048477-23-000041.json
- Plain text: https://secwatch.observer/filing/0001048477-23-000041.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC updated its full-year 2023 guidance (reaffirmed).
  - Period: full-year 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: "Results in the quarter drove double-digit revenue growth year-over-year and supports BioMarin’s full-year 2023 revenue and profitability objectives, set at the beginning of the year,"
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC reported third quarter ended September 30, 2023 results: revenue $581.3 million, net income $40.4 million, EPS $0.21.
  - Period: third quarter ended September 30, 2023
  - Revenue: $581.3 million
  - Net income: $40.4 million
  - EPS: $0.21
  - Result: reported results
  source text: facilitate patient access, setting the stage for meaningful uptake of ROCTAVIAN in 2024.” Third Quarter Financial Highlights: • Total Revenues for the third quarter of 2023 were $581.3 million, an increase of 15% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to the following: ◦ higher VOXZOGO sales volume due to new
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.